Home Medical Devices Preclinical CRO Market Size, Growth & Demand | 2033

Preclinical CRO Market Size, Share & Trends Analysis Report By Service (Bioanalysis and DMPK studies, Toxicology Testing, Compound Management, Chemistry, Safety Pharmacology, Others), By Model (Patient-Derived Organoid (PDO) Model, Patient-Derived Xenograft Model), By Applications (Oncology, Neurology, Cardiology, Infectious Diseases, Metabolic Disorders, Others), By End-User (Pharmaceutical and Biotechnological Companies, Government and Academic Institutes, Medical Device Companies, Others) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2025-2033

Report Code: SRMD54943DR
Last Updated : Oct 11, 2024
Author : Straits Research
Starting From
USD 2300
Buy Now

Table Of Content

  1. Executive Summary

    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends

    1. Global Preclinical CRO Market Introduction
    2. By Service
      1. Introduction
        1. Service By Value
      2. Bioanalysis and DMPK studies
        1. By Value
        2. In vitro ADME
          1. In vitro ADME By Value
        3. In-vivo PK
          1. In-vivo PK By Value
      3. Toxicology Testing
        1. By Value
        2. GLP
          1. GLP By Value
        3. Non-GLP
          1. Non-GLP By Value
      4. Compound Management
        1. By Value
        2. Process R&D
          1. Process R&D By Value
        3. Custom Synthesis
          1. Custom Synthesis By Value
        4. Others
          1. Others By Value
      5. Chemistry
        1. By Value
        2. Medicinal Chemistry
          1. Medicinal Chemistry By Value
        3. Computation Chemistry
          1. Computation Chemistry By Value
      6. Safety Pharmacology
        1. By Value
      7. Others
        1. By Value
    3. By Model
      1. Introduction
        1. Model By Value
      2. Patient-Derived Organoid (PDO) Model
        1. By Value
      3. Patient-Derived Xenograft Model
        1. By Value
    4. By Applications
      1. Introduction
        1. Applications By Value
      2. Oncology
        1. By Value
      3. Neurology
        1. By Value
      4. Cardiology
        1. By Value
      5. Infectious Diseases
        1. By Value
      6. Metabolic Disorders
        1. By Value
      7. Others
        1. By Value
    5. By End-User
      1. Introduction
        1. End-User By Value
      2. Pharmaceutical and Biotechnological Companies
        1. By Value
      3. Government and Academic Institutes
        1. By Value
      4. Medical Device Companies
        1. By Value
      5. Others
        1. By Value
    1. Introduction
    2. By Service
      1. Introduction
        1. Service By Value
      2. Bioanalysis and DMPK studies
        1. By Value
        2. In vitro ADME
          1. In vitro ADME By Value
        3. In-vivo PK
          1. In-vivo PK By Value
      3. Toxicology Testing
        1. By Value
        2. GLP
          1. GLP By Value
        3. Non-GLP
          1. Non-GLP By Value
      4. Compound Management
        1. By Value
        2. Process R&D
          1. Process R&D By Value
        3. Custom Synthesis
          1. Custom Synthesis By Value
        4. Others
          1. Others By Value
      5. Chemistry
        1. By Value
        2. Medicinal Chemistry
          1. Medicinal Chemistry By Value
        3. Computation Chemistry
          1. Computation Chemistry By Value
      6. Safety Pharmacology
        1. By Value
      7. Others
        1. By Value
    3. By Model
      1. Introduction
        1. Model By Value
      2. Patient-Derived Organoid (PDO) Model
        1. By Value
      3. Patient-Derived Xenograft Model
        1. By Value
    4. By Applications
      1. Introduction
        1. Applications By Value
      2. Oncology
        1. By Value
      3. Neurology
        1. By Value
      4. Cardiology
        1. By Value
      5. Infectious Diseases
        1. By Value
      6. Metabolic Disorders
        1. By Value
      7. Others
        1. By Value
    5. By End-User
      1. Introduction
        1. End-User By Value
      2. Pharmaceutical and Biotechnological Companies
        1. By Value
      3. Government and Academic Institutes
        1. By Value
      4. Medical Device Companies
        1. By Value
      5. Others
        1. By Value
    6. U.S.
      1. By Service
        1. Introduction
          1. Service By Value
        2. Bioanalysis and DMPK studies
          1. By Value
          2. In vitro ADME
            1. In vitro ADME By Value
          3. In-vivo PK
            1. In-vivo PK By Value
        3. Toxicology Testing
          1. By Value
          2. GLP
            1. GLP By Value
          3. Non-GLP
            1. Non-GLP By Value
        4. Compound Management
          1. By Value
          2. Process R&D
            1. Process R&D By Value
          3. Custom Synthesis
            1. Custom Synthesis By Value
          4. Others
            1. Others By Value
        5. Chemistry
          1. By Value
          2. Medicinal Chemistry
            1. Medicinal Chemistry By Value
          3. Computation Chemistry
            1. Computation Chemistry By Value
        6. Safety Pharmacology
          1. By Value
        7. Others
          1. By Value
      2. By Model
        1. Introduction
          1. Model By Value
        2. Patient-Derived Organoid (PDO) Model
          1. By Value
        3. Patient-Derived Xenograft Model
          1. By Value
      3. By Applications
        1. Introduction
          1. Applications By Value
        2. Oncology
          1. By Value
        3. Neurology
          1. By Value
        4. Cardiology
          1. By Value
        5. Infectious Diseases
          1. By Value
        6. Metabolic Disorders
          1. By Value
        7. Others
          1. By Value
      4. By End-User
        1. Introduction
          1. End-User By Value
        2. Pharmaceutical and Biotechnological Companies
          1. By Value
        3. Government and Academic Institutes
          1. By Value
        4. Medical Device Companies
          1. By Value
        5. Others
          1. By Value
    7. Canada
    1. Introduction
    2. By Service
      1. Introduction
        1. Service By Value
      2. Bioanalysis and DMPK studies
        1. By Value
        2. In vitro ADME
          1. In vitro ADME By Value
        3. In-vivo PK
          1. In-vivo PK By Value
      3. Toxicology Testing
        1. By Value
        2. GLP
          1. GLP By Value
        3. Non-GLP
          1. Non-GLP By Value
      4. Compound Management
        1. By Value
        2. Process R&D
          1. Process R&D By Value
        3. Custom Synthesis
          1. Custom Synthesis By Value
        4. Others
          1. Others By Value
      5. Chemistry
        1. By Value
        2. Medicinal Chemistry
          1. Medicinal Chemistry By Value
        3. Computation Chemistry
          1. Computation Chemistry By Value
      6. Safety Pharmacology
        1. By Value
      7. Others
        1. By Value
    3. By Model
      1. Introduction
        1. Model By Value
      2. Patient-Derived Organoid (PDO) Model
        1. By Value
      3. Patient-Derived Xenograft Model
        1. By Value
    4. By Applications
      1. Introduction
        1. Applications By Value
      2. Oncology
        1. By Value
      3. Neurology
        1. By Value
      4. Cardiology
        1. By Value
      5. Infectious Diseases
        1. By Value
      6. Metabolic Disorders
        1. By Value
      7. Others
        1. By Value
    5. By End-User
      1. Introduction
        1. End-User By Value
      2. Pharmaceutical and Biotechnological Companies
        1. By Value
      3. Government and Academic Institutes
        1. By Value
      4. Medical Device Companies
        1. By Value
      5. Others
        1. By Value
    6. U.K.
      1. By Service
        1. Introduction
          1. Service By Value
        2. Bioanalysis and DMPK studies
          1. By Value
          2. In vitro ADME
            1. In vitro ADME By Value
          3. In-vivo PK
            1. In-vivo PK By Value
        3. Toxicology Testing
          1. By Value
          2. GLP
            1. GLP By Value
          3. Non-GLP
            1. Non-GLP By Value
        4. Compound Management
          1. By Value
          2. Process R&D
            1. Process R&D By Value
          3. Custom Synthesis
            1. Custom Synthesis By Value
          4. Others
            1. Others By Value
        5. Chemistry
          1. By Value
          2. Medicinal Chemistry
            1. Medicinal Chemistry By Value
          3. Computation Chemistry
            1. Computation Chemistry By Value
        6. Safety Pharmacology
          1. By Value
        7. Others
          1. By Value
      2. By Model
        1. Introduction
          1. Model By Value
        2. Patient-Derived Organoid (PDO) Model
          1. By Value
        3. Patient-Derived Xenograft Model
          1. By Value
      3. By Applications
        1. Introduction
          1. Applications By Value
        2. Oncology
          1. By Value
        3. Neurology
          1. By Value
        4. Cardiology
          1. By Value
        5. Infectious Diseases
          1. By Value
        6. Metabolic Disorders
          1. By Value
        7. Others
          1. By Value
      4. By End-User
        1. Introduction
          1. End-User By Value
        2. Pharmaceutical and Biotechnological Companies
          1. By Value
        3. Government and Academic Institutes
          1. By Value
        4. Medical Device Companies
          1. By Value
        5. Others
          1. By Value
    7. Germany
    8. France
    9. Spain
    10. Italy
    11. Russia
    12. Nordic
    13. Benelux
    14. Rest of Europe
    1. Introduction
    2. By Service
      1. Introduction
        1. Service By Value
      2. Bioanalysis and DMPK studies
        1. By Value
        2. In vitro ADME
          1. In vitro ADME By Value
        3. In-vivo PK
          1. In-vivo PK By Value
      3. Toxicology Testing
        1. By Value
        2. GLP
          1. GLP By Value
        3. Non-GLP
          1. Non-GLP By Value
      4. Compound Management
        1. By Value
        2. Process R&D
          1. Process R&D By Value
        3. Custom Synthesis
          1. Custom Synthesis By Value
        4. Others
          1. Others By Value
      5. Chemistry
        1. By Value
        2. Medicinal Chemistry
          1. Medicinal Chemistry By Value
        3. Computation Chemistry
          1. Computation Chemistry By Value
      6. Safety Pharmacology
        1. By Value
      7. Others
        1. By Value
    3. By Model
      1. Introduction
        1. Model By Value
      2. Patient-Derived Organoid (PDO) Model
        1. By Value
      3. Patient-Derived Xenograft Model
        1. By Value
    4. By Applications
      1. Introduction
        1. Applications By Value
      2. Oncology
        1. By Value
      3. Neurology
        1. By Value
      4. Cardiology
        1. By Value
      5. Infectious Diseases
        1. By Value
      6. Metabolic Disorders
        1. By Value
      7. Others
        1. By Value
    5. By End-User
      1. Introduction
        1. End-User By Value
      2. Pharmaceutical and Biotechnological Companies
        1. By Value
      3. Government and Academic Institutes
        1. By Value
      4. Medical Device Companies
        1. By Value
      5. Others
        1. By Value
    6. China
      1. By Service
        1. Introduction
          1. Service By Value
        2. Bioanalysis and DMPK studies
          1. By Value
          2. In vitro ADME
            1. In vitro ADME By Value
          3. In-vivo PK
            1. In-vivo PK By Value
        3. Toxicology Testing
          1. By Value
          2. GLP
            1. GLP By Value
          3. Non-GLP
            1. Non-GLP By Value
        4. Compound Management
          1. By Value
          2. Process R&D
            1. Process R&D By Value
          3. Custom Synthesis
            1. Custom Synthesis By Value
          4. Others
            1. Others By Value
        5. Chemistry
          1. By Value
          2. Medicinal Chemistry
            1. Medicinal Chemistry By Value
          3. Computation Chemistry
            1. Computation Chemistry By Value
        6. Safety Pharmacology
          1. By Value
        7. Others
          1. By Value
      2. By Model
        1. Introduction
          1. Model By Value
        2. Patient-Derived Organoid (PDO) Model
          1. By Value
        3. Patient-Derived Xenograft Model
          1. By Value
      3. By Applications
        1. Introduction
          1. Applications By Value
        2. Oncology
          1. By Value
        3. Neurology
          1. By Value
        4. Cardiology
          1. By Value
        5. Infectious Diseases
          1. By Value
        6. Metabolic Disorders
          1. By Value
        7. Others
          1. By Value
      4. By End-User
        1. Introduction
          1. End-User By Value
        2. Pharmaceutical and Biotechnological Companies
          1. By Value
        3. Government and Academic Institutes
          1. By Value
        4. Medical Device Companies
          1. By Value
        5. Others
          1. By Value
    7. Korea
    8. Japan
    9. India
    10. Australia
    11. Singapore
    12. Taiwan
    13. South East Asia
    14. Rest of Asia-Pacific
    1. Introduction
    2. By Service
      1. Introduction
        1. Service By Value
      2. Bioanalysis and DMPK studies
        1. By Value
        2. In vitro ADME
          1. In vitro ADME By Value
        3. In-vivo PK
          1. In-vivo PK By Value
      3. Toxicology Testing
        1. By Value
        2. GLP
          1. GLP By Value
        3. Non-GLP
          1. Non-GLP By Value
      4. Compound Management
        1. By Value
        2. Process R&D
          1. Process R&D By Value
        3. Custom Synthesis
          1. Custom Synthesis By Value
        4. Others
          1. Others By Value
      5. Chemistry
        1. By Value
        2. Medicinal Chemistry
          1. Medicinal Chemistry By Value
        3. Computation Chemistry
          1. Computation Chemistry By Value
      6. Safety Pharmacology
        1. By Value
      7. Others
        1. By Value
    3. By Model
      1. Introduction
        1. Model By Value
      2. Patient-Derived Organoid (PDO) Model
        1. By Value
      3. Patient-Derived Xenograft Model
        1. By Value
    4. By Applications
      1. Introduction
        1. Applications By Value
      2. Oncology
        1. By Value
      3. Neurology
        1. By Value
      4. Cardiology
        1. By Value
      5. Infectious Diseases
        1. By Value
      6. Metabolic Disorders
        1. By Value
      7. Others
        1. By Value
    5. By End-User
      1. Introduction
        1. End-User By Value
      2. Pharmaceutical and Biotechnological Companies
        1. By Value
      3. Government and Academic Institutes
        1. By Value
      4. Medical Device Companies
        1. By Value
      5. Others
        1. By Value
    6. UAE
      1. By Service
        1. Introduction
          1. Service By Value
        2. Bioanalysis and DMPK studies
          1. By Value
          2. In vitro ADME
            1. In vitro ADME By Value
          3. In-vivo PK
            1. In-vivo PK By Value
        3. Toxicology Testing
          1. By Value
          2. GLP
            1. GLP By Value
          3. Non-GLP
            1. Non-GLP By Value
        4. Compound Management
          1. By Value
          2. Process R&D
            1. Process R&D By Value
          3. Custom Synthesis
            1. Custom Synthesis By Value
          4. Others
            1. Others By Value
        5. Chemistry
          1. By Value
          2. Medicinal Chemistry
            1. Medicinal Chemistry By Value
          3. Computation Chemistry
            1. Computation Chemistry By Value
        6. Safety Pharmacology
          1. By Value
        7. Others
          1. By Value
      2. By Model
        1. Introduction
          1. Model By Value
        2. Patient-Derived Organoid (PDO) Model
          1. By Value
        3. Patient-Derived Xenograft Model
          1. By Value
      3. By Applications
        1. Introduction
          1. Applications By Value
        2. Oncology
          1. By Value
        3. Neurology
          1. By Value
        4. Cardiology
          1. By Value
        5. Infectious Diseases
          1. By Value
        6. Metabolic Disorders
          1. By Value
        7. Others
          1. By Value
      4. By End-User
        1. Introduction
          1. End-User By Value
        2. Pharmaceutical and Biotechnological Companies
          1. By Value
        3. Government and Academic Institutes
          1. By Value
        4. Medical Device Companies
          1. By Value
        5. Others
          1. By Value
    7. Turkey
    8. Saudi Arabia
    9. South Africa
    10. Egypt
    11. Nigeria
    12. Rest of MEA
    1. Introduction
    2. By Service
      1. Introduction
        1. Service By Value
      2. Bioanalysis and DMPK studies
        1. By Value
        2. In vitro ADME
          1. In vitro ADME By Value
        3. In-vivo PK
          1. In-vivo PK By Value
      3. Toxicology Testing
        1. By Value
        2. GLP
          1. GLP By Value
        3. Non-GLP
          1. Non-GLP By Value
      4. Compound Management
        1. By Value
        2. Process R&D
          1. Process R&D By Value
        3. Custom Synthesis
          1. Custom Synthesis By Value
        4. Others
          1. Others By Value
      5. Chemistry
        1. By Value
        2. Medicinal Chemistry
          1. Medicinal Chemistry By Value
        3. Computation Chemistry
          1. Computation Chemistry By Value
      6. Safety Pharmacology
        1. By Value
      7. Others
        1. By Value
    3. By Model
      1. Introduction
        1. Model By Value
      2. Patient-Derived Organoid (PDO) Model
        1. By Value
      3. Patient-Derived Xenograft Model
        1. By Value
    4. By Applications
      1. Introduction
        1. Applications By Value
      2. Oncology
        1. By Value
      3. Neurology
        1. By Value
      4. Cardiology
        1. By Value
      5. Infectious Diseases
        1. By Value
      6. Metabolic Disorders
        1. By Value
      7. Others
        1. By Value
    5. By End-User
      1. Introduction
        1. End-User By Value
      2. Pharmaceutical and Biotechnological Companies
        1. By Value
      3. Government and Academic Institutes
        1. By Value
      4. Medical Device Companies
        1. By Value
      5. Others
        1. By Value
    6. Brazil
      1. By Service
        1. Introduction
          1. Service By Value
        2. Bioanalysis and DMPK studies
          1. By Value
          2. In vitro ADME
            1. In vitro ADME By Value
          3. In-vivo PK
            1. In-vivo PK By Value
        3. Toxicology Testing
          1. By Value
          2. GLP
            1. GLP By Value
          3. Non-GLP
            1. Non-GLP By Value
        4. Compound Management
          1. By Value
          2. Process R&D
            1. Process R&D By Value
          3. Custom Synthesis
            1. Custom Synthesis By Value
          4. Others
            1. Others By Value
        5. Chemistry
          1. By Value
          2. Medicinal Chemistry
            1. Medicinal Chemistry By Value
          3. Computation Chemistry
            1. Computation Chemistry By Value
        6. Safety Pharmacology
          1. By Value
        7. Others
          1. By Value
      2. By Model
        1. Introduction
          1. Model By Value
        2. Patient-Derived Organoid (PDO) Model
          1. By Value
        3. Patient-Derived Xenograft Model
          1. By Value
      3. By Applications
        1. Introduction
          1. Applications By Value
        2. Oncology
          1. By Value
        3. Neurology
          1. By Value
        4. Cardiology
          1. By Value
        5. Infectious Diseases
          1. By Value
        6. Metabolic Disorders
          1. By Value
        7. Others
          1. By Value
      4. By End-User
        1. Introduction
          1. End-User By Value
        2. Pharmaceutical and Biotechnological Companies
          1. By Value
        3. Government and Academic Institutes
          1. By Value
        4. Medical Device Companies
          1. By Value
        5. Others
          1. By Value
    7. Mexico
    8. Argentina
    9. Chile
    10. Colombia
    11. Rest of LATAM
    1. Preclinical CRO Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. Charles River Laboratories International, Inc.
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Covance Inc.
    3. ICON plc
    4. Medpace, Inc.
    5. WuXi AppTec
    6. Envigo
    7. PRA Health Sciences
    8. Syngene International Limited
    9. Eurofins Scientific
    10. Parexel International Corporation
    11. SGS SA
    12. MPI Research
    13. Crown Bioscience, Inc.
    14. Toxikon Corporation
    15. Pharmaron
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Related Reports

Global Report
The global bispecific antibodies market size was valued at USD 8.2 billion in 2023 and is projected to reach a value of USD 224.6 billion by 2032, registering a CAGR of 44.4% during the forecast period (2024-2032). The rise in cancer incidence is a c
Buy Now
Global Report
The global X-Ray Inspection System Market size was valued at USD 734.5 Million in 2022 and is projected to reach USD 1231.3 Million by 2031, registering a CAGR of 6.6% during the forecast period (2023-2031). The rising awareness of the bene
Buy Now
Global Report
Inflight Catering Market Size and Trends The global inflight catering market size was valued at USD 13.62 billion in 2023. It is projected to reach from USD 15.16 billion in 2024 to USD 35.75 billion by 2032, growing at a CAGR of 11.32% during the f
Buy Now
Global Report
Bladder Scanners Market Size The global bladder scanners market size was valued at USD 149.28 million in 2024 and is projected to grow from USD 162.36 million in 2025 to reach USD 270.46 million by 2033, exhibiting a CA
Buy Now
Global Report
Hair Removal Wax Market Size The global hair removal wax market size was valued at USD 14426.26 million in 2024 and is projected to reach from USD 15133.14 million in 2025 to USD 22188.76 million by 2033, growing at a CAGR of 4.9% during t
Buy Now

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report


We are featured on :